Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol

By afschroeder • August 29, 2025

Holzgreve A, Delker A, Ells Z, Brosch-Lenz J, Unterrainer LM, Nikitas J, Zhu S, Contreras MM, Alam H, Nabong RM, Lira S, Vasilyev A, Chen L, Grogan T, Elashoff D, Meyer CA, Dahlbom M, Czernin J, Calais J. Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of ¹⁷⁷Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. J Nucl Med. 2025 Aug 28:jnumed.125.269495. doi: 10.2967/jnumed.125.269495. Epub ahead of print. PMID: 40876952.

Tags: [177Lu]Lu-PSMA-617, DOM STAT, General Internal Medicine, mCRPC, metastatic castration-resistant prostate cancer, Primary Care, prostate-specific membrane antigen, PSMA, Publications, radiopharmaceutical therapy, RPT, SPECT/CT, therapy response assessment, treatment holidays

William J. Carroll, MD, FACP Appointed Section Chief of Palliative Care and Extensivist Medicine

The UCLA Department of Medicine (DoM) is pleased to announce the appointment of William J. Carroll, MD, FACPas section chief of the UCLA DoM Palliative Care[...]

Joshua N. Khalili, MD Appointed to DoM Chief Wellness Officer

The UCLA Department of Medicine has appointed Joshua N. Khalili, MD to chief wellness officer (CWO) effective April 1. The appointment builds on Dr. Khalili’s outstanding work[...]

Sun M. Yoo, MD, MPH to Depart DoM to Pursue New Leadership Opportunity

The UCLA Department of Medicine (DoM) announces that Sun M. Yoo, MD, MPH, will be departing UCLA Health to assume the role of a founding chief[...]